Danish biotechnology company focused on developing antibody-based therapies for cancer and other serious diseases. Its portfolio includes proprietary oncology drugs and partnerships with major pharmaceutical companies, generating significant royalty revenue from treatments such as multiple myeloma t...
3 members of Congress have disclosed 11 trades in Genmab A/S (GMAB), a Healthcare company. The buy/sell breakdown shows 6 purchases versus 5 sales, indicating net buying interest from lawmakers. All data is sourced from STOCK Act periodic transaction reports filed with Congress.
| Date | Politician | Type | Amount |
|---|---|---|---|
| 2025-01-16 | Josh Gottheimer | buy | $1K – $15K |
| 2024-12-16 | Josh Gottheimer | sell | $1K – $15K |
| 2024-07-19 | Josh Gottheimer | buy | $1K – $15K |
| 2024-06-18 | Josh Gottheimer | sell | $1K – $15K |
| 2023-10-16 | Josh Gottheimer | buy | $1K – $15K |
| 2023-09-15 | Josh Gottheimer | sell | $1K – $15K |
| 2023-07-20 | Josh Gottheimer | buy | $1K – $15K |
| 2023-07-19 | Josh Gottheimer | buy | $1K – $15K |
| 2023-07-10 | Daniel Goldman | sell | $50K – $100K |
| 2023-03-31 | Daniel Goldman | sell | $1K – $15K |
| 2020-11-20 | Thomas R Carper | buy | $1K – $15K |